<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Thorac Cancer</journal-id>
      <journal-id journal-id-type="iso-abbrev">Thorac Cancer</journal-id>
      <journal-id journal-id-type="doi">10.1111/(ISSN)1759-7714</journal-id>
      <journal-id journal-id-type="publisher-id">TCA</journal-id>
      <journal-title-group>
        <journal-title>Thoracic Cancer</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1759-7706</issn>
      <issn pub-type="epub">1759-7714</issn>
      <publisher>
        <publisher-name>John Wiley &amp; Sons Australia, Ltd</publisher-name>
        <publisher-loc>Melbourne</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">28102933</article-id>
      <article-id pub-id-type="pmc">5334306</article-id>
      <article-id pub-id-type="doi">10.1111/1759-7714.12405</article-id>
      <article-id pub-id-type="publisher-id">TCA12405</article-id>
      <article-categories>
        <subj-group subj-group-type="overline">
          <subject>Case Report</subject>
        </subj-group>
        <subj-group subj-group-type="heading">
          <subject>Case Reports</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>What if a tumor is significantly enlarged just before stereotactic body radiation therapy? <styled-content style="fixed-case">A</styled-content> case report and review of the literature</article-title>
        <alt-title alt-title-type="right-running-head">Tumor enlargement before <styled-content style="fixed-case">SBRT</styled-content></alt-title>
        <alt-title alt-title-type="left-running-head">H.&#x2010;J. Chen <italic>et al.</italic></alt-title>
      </title-group>
      <contrib-group>
        <contrib id="tca12405-cr-0001" contrib-type="author">
          <name>
            <surname>Chen</surname>
            <given-names>Hung&#x2010;Jen</given-names>
          </name>
          <xref ref-type="aff" rid="tca12405-aff-0001">
<sup>1</sup>
</xref>
          <xref ref-type="author-notes" rid="tca12405-note-0001">
<sup>&#x2020;</sup>
</xref>
        </contrib>
        <contrib id="tca12405-cr-0002" contrib-type="author">
          <name>
            <surname>Liang</surname>
            <given-names>Ji&#x2010;An</given-names>
          </name>
          <xref ref-type="aff" rid="tca12405-aff-0002">
<sup>2</sup>
</xref>
          <xref ref-type="author-notes" rid="tca12405-note-0001">
<sup>&#x2020;</sup>
</xref>
        </contrib>
        <contrib id="tca12405-cr-0003" contrib-type="author">
          <name>
            <surname>Chen</surname>
            <given-names>Chih&#x2010;Yi</given-names>
          </name>
          <xref ref-type="aff" rid="tca12405-aff-0003">
<sup>3</sup>
</xref>
          <xref ref-type="author-notes" rid="tca12405-note-0001">
<sup>&#x2020;</sup>
</xref>
        </contrib>
        <contrib id="tca12405-cr-0004" contrib-type="author">
          <name>
            <surname>Yu</surname>
            <given-names>Yang&#x2010;Hao</given-names>
          </name>
          <xref ref-type="aff" rid="tca12405-aff-0001">
<sup>1</sup>
</xref>
          <xref ref-type="author-notes" rid="tca12405-note-0001">
<sup>&#x2020;</sup>
</xref>
        </contrib>
        <contrib id="tca12405-cr-0005" contrib-type="author" corresp="yes">
          <name>
            <surname>Chien</surname>
            <given-names>Chun&#x2010;Ru</given-names>
          </name>
          <address>
            <email>d16181@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="tca12405-aff-0004">
<sup>4</sup>
</xref>
        </contrib>
      </contrib-group>
      <aff id="tca12405-aff-0001">
        <label>
          <sup>1</sup>
        </label>
        <named-content content-type="organisation-division">Division of Pulmonary and Critical Care, Department of Internal Medicine</named-content>
        <institution>China Medical University Hospital</institution>
        <named-content content-type="city">Taichung</named-content>
        <country country="TW">Taiwan</country>
      </aff>
      <aff id="tca12405-aff-0002">
        <label>
          <sup>2</sup>
        </label>
        <named-content content-type="organisation-division">Department of Radiation Oncology, Cancer Center</named-content>
        <institution>China Medical University Hospital</institution>
        <named-content content-type="city">Taichung</named-content>
        <country country="TW">Taiwan</country>
      </aff>
      <aff id="tca12405-aff-0003">
        <label>
          <sup>3</sup>
        </label>
        <named-content content-type="organisation-division">Department of Chest Surgery</named-content>
        <institution>Chung Shan Medical University</institution>
        <named-content content-type="city">Taichung</named-content>
        <country country="TW">Taiwan</country>
      </aff>
      <aff id="tca12405-aff-0004">
        <label>
          <sup>4</sup>
        </label>
        <named-content content-type="organisation-division">Department of Radiation Oncology, Cancer Center, China Medical University Hospital; School of Medicine, College of Medicine</named-content>
        <institution>China Medical University</institution>
        <named-content content-type="city">Taichung</named-content>
        <country country="TW">Taiwan</country>
      </aff>
      <author-notes>
        <corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Chun&#x2010;Ru Chien, School of Medicine, College of Medicine, China Medical University, No. 91 Hsueh&#x2010;Shih Road, Taichung 40402, Taiwan.<break/>
Tel: +886 4 22052121 ext 7450<break/>
Fax: +886 4 22052121 ext 7460<break/>
Email: <email>d16181@gmail.com</email><break/></corresp>
        <fn id="tca12405-note-0001">
          <label>&#x2020;</label>
          <p>Equal contribution.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub">
        <day>18</day>
        <month>11</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>3</month>
        <year>2017</year>
      </pub-date>
      <volume>8</volume>
      <issue>2</issue>
      <issue-id pub-id-type="doi">10.1111/tca.2017.8.issue-2</issue-id>
      <fpage>118</fpage>
      <lpage>120</lpage>
      <history>
        <date date-type="received">
          <day>09</day>
          <month>9</month>
          <year>2016</year>
        </date>
        <date date-type="rev-recd">
          <day>30</day>
          <month>9</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>07</day>
          <month>10</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2017 China Lung Oncology Group and John Wiley & Sons Australia, Ltd <copyright-statement>-->
        <copyright-statement content-type="article-copyright">&#xA9; 2016 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley &amp; Sons Australia, Ltd</copyright-statement>
        <license license-type="creativeCommonsBy-nc">
          <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">Creative Commons Attribution&#x2010;NonCommercial</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p>
        </license>
      </permissions>
      <self-uri content-type="pdf" xlink:type="simple" xlink:href="file:TCA-8-118.pdf"/>
      <abstract>
        <p>Stereotactic body radiation therapy (<styled-content style="fixed-case">SBRT</styled-content>) plays an important role in early stage non&#x2010;small cell lung cancer. Tumor growth before radiotherapy planning (<styled-content style="fixed-case">RTP</styled-content>) or during <styled-content style="fixed-case">SBRT</styled-content> has been reported in lung cancer patients; however, little is known of growth during the period in&#x2010;between (i.e. after <styled-content style="fixed-case">RTP</styled-content> but before <styled-content style="fixed-case">SBRT</styled-content>). An 83&#x2010;year&#x2010;old man referred to our hospital and diagnosed with medically inoperable non&#x2010;small cell lung cancer was noted to have significant tumor progression on <styled-content style="fixed-case">d</styled-content>ay 1 of cone beam computed tomography just before the planned <styled-content style="fixed-case">SBRT</styled-content> delivery. Because of uncertainty of the underlying etiology and unfamiliarity with this phenomenon, we made a clinical decision to arrange re&#x2010;simulation and revise our treatment to conventional fractionated radiotherapy (<styled-content style="fixed-case">CFRT</styled-content>). After an initial response, distant metastases occurred eight&#x2009;months after <styled-content style="fixed-case">CFRT.</styled-content> The patient received best supportive care and was under hospice care at the last follow&#x2010;up (27&#x2009;months after <styled-content style="fixed-case">CFRT</styled-content>). We report a case with significant tumor growth just before planned <styled-content style="fixed-case">SBRT</styled-content>. Optimal management in this scenario requires further investigation.</p>
      </abstract>
      <kwd-group kwd-group-type="author-generated">
        <kwd id="tca12405-kwd-0001"><styled-content style="fixed-case">I</styled-content>mage&#x2010;guidance radiotherapy</kwd>
        <kwd id="tca12405-kwd-0002">lung cancer</kwd>
        <kwd id="tca12405-kwd-0003">stereotactic body radiation therapy</kwd>
      </kwd-group>
      <funding-group>
        <award-group>
          <funding-source>China Medical University Hospital</funding-source>
          <award-id>DMR&#x2010;105&#x2010;046</award-id>
        </award-group>
      </funding-group>
      <counts>
        <fig-count count="1"/>
        <table-count count="0"/>
        <page-count count="3"/>
        <word-count count="1633"/>
      </counts>
      <custom-meta-group>
        <custom-meta>
          <meta-name>source-schema-version-number</meta-name>
          <meta-value>2.0</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>component-id</meta-name>
          <meta-value>tca12405</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>cover-date</meta-name>
          <meta-value>March 2017</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>details-of-publishers-convertor</meta-name>
          <meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.0.8 mode:remove_FC converted:02.03.2017</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="tca12405-sec-0001">
      <title>Introduction</title>
      <p>Stereotactic body radiation therapy (SBRT) plays an important role in early stage non&#x2010;small cell lung cancer (NSCLC), in which image guidance plays a crucial role.<xref rid="tca12405-bib-0001" ref-type="ref">1</xref>, <xref rid="tca12405-bib-0002" ref-type="ref">2</xref>, <xref rid="tca12405-bib-0003" ref-type="ref">3</xref>, <xref rid="tca12405-bib-0004" ref-type="ref">4</xref> But what if the tumor is significantly enlarged just before SBRT and image guidance is no longer feasible? Herein we report our experience of a such a case. The research ethics committee of our institution approved this study (CMUH105&#x2010;REC2&#x2010;070).</p>
    </sec>
    <sec id="tca12405-sec-0002">
      <title>Case report</title>
      <p>An 83&#x2010;year&#x2010;old man was diagnosed with medically inoperable clinical stage T2N0M0 right upper lobe NSCLC by bronchoscopic exam (patent airway, but endobronchial ultrasound&#x2010;guided biopsy revealed large cell carcinoma), followed by positron emission tomography&#x2010;computed tomography (PET&#x2010;CT) after a chest X&#x2010;ray revealed abnormal results during routine surveillance for chronic obstructive pulmonary disease. He was referred for SBRT on July 15, 2013. Radiotherapy simulation was arranged on July 17, 2013 using abdominal compression with free breathing CT, complemented with inhale/exhale CT. We used a clinical target volume of at least 5&#x2009;mm around the gross tumor and a 5&#x2009;mm planned target volume margin, and planned for 62Gy/10Fx (for a biological equivalent dose of around 100&#x2009;Gy10) (Fig <xref rid="tca12405-fig-0001" ref-type="fig">1</xref>a). The tumor shape was relatively spherical, with a volume of 11.4&#x2009;cc. Although the patient was well and did not experience any discomfort, such as fever or cough, during the period between RTP to planned SBRT, the tumor was found to be significantly enlarged after verification using cone&#x2010;beam computed tomography (CBCT) on day 1 (August 1, 2013) of the planned SBRT (Fig <xref rid="tca12405-fig-0001" ref-type="fig">1</xref>b). The center of the tumor mass had changed significantly. Because of the uncertainty regarding his underlying disease status, we ceased plans for SBRT and arranged alternate simulation treatment for August 2, 2014 (Fig <xref rid="tca12405-fig-0001" ref-type="fig">1</xref>c). At that time, the tumor was larger (volume 29.9&#x2009;cc) with an altered shape, elongating toward the cranial/lateral side. As we expected, the original SBRT plan could not fully cover the current tumor, especially at the cranial/lateral part (Fig <xref rid="tca12405-fig-0001" ref-type="fig">1</xref>d). Although there was a bronchus located within the initial tumor mass and we could not exclude the possibility of atelectasis, we were still uncomfortable regarding the true etiology. We decided that it was impractical to consider repeating a pathological exam and PET&#x2010;CT. We changed our plan to conventional fractionated radiotherapy (CFRT) of 74 Gy in 37 fractions (74 Gy but not 60Gy for radiotherapy only) after discussion with referring physicians. The patient completed the treatment without incident and showed an initial response on follow&#x2010;up computed tomography (CT) on November 21, 2013. However, during a subsequent CT on April 2, 2014, new lung metastasis was detected. The patient received best supportive care thereafter and was under hospice care at last follow&#x2010;up (November 26, 2015).</p>
      <fig fig-type="Figure" xml:lang="en" id="tca12405-fig-0001" orientation="portrait" position="float">
        <label>Figure 1</label>
        <caption>
          <p>Tumor image on (<bold>a</bold>) initial simulation (gross tumor volume, <styled-content style="fixed-case">GTV</styled-content>&#x2009;=&#x2009;11.4&#x2009;cc), (<bold>b</bold>) cone&#x2010;beam computed tomography, (<bold>c</bold>) re&#x2010;simulation (<styled-content style="fixed-case">GTV</styled-content>&#x2009;=&#x2009;30&#x2009;cc), and (<bold>d</bold>) re&#x2010;simulation and isodose distribution, if treated using the original plan. Please note, axial images were not presented at the same level but at the level with the greatest diameter; therefore, the orthogonal image was also displaced.</p>
        </caption>
        <graphic id="nlm-graphic-1" xlink:href="TCA-8-118-g001"/>
      </fig>
    </sec>
    <sec id="tca12405-sec-0003">
      <title>Discussion</title>
      <p>We searched PubMed using (lung cancer) AND ((stereotactic body radiotherapy) OR (stereotactic ablative radiotherapy)) AND ((volume*) OR (enlarged) OR (growth) OR (progressed) OR (progression)) as keywords to find relevant studies. Among 1083 studies, we found that tumor growth before radiotherapy planning (RTP) in lung cancer patients treated with SBRT had been reported.<xref rid="tca12405-bib-0005" ref-type="ref">5</xref> There were also studies reporting potential tumor growth during SBRT.<xref rid="tca12405-bib-0006" ref-type="ref">6</xref> However, less is known of the period in&#x2010;between (i.e. after RTP but before SBRT), as seen in this case. Murai <italic>et al.</italic> investigated potential tumor growth from &#x201C;CT to before referral&#x201D; to &#x201C;CT for treatment planning or positioning before SBRT&#x201D; in 201 patients. In the time period from diagnostic CT to simulation or positional CT (i.e. start of RTP or CBCT, respectively), no T stage progression was found in 41 of the patients. However, this study did not differentiate &#x201C;from diagnosis to simulation&#x201D; and &#x201C;from simulation to treatment&#x201D; (the in&#x2010;between period in our study).<xref rid="tca12405-bib-0007" ref-type="ref">7</xref> Salamekh <italic>et al.</italic> evaluated the trend of tumor growth of 18 lung tumors from 15 cases. They found no obvious tumor enlargement in the first CBCT when compared with tumor contouring on the planning CT. However, the interval from simulation to CBCT was not reported in this study.<xref rid="tca12405-bib-0008" ref-type="ref">8</xref> Although a wait time of up to four&#x2009;weeks has been reported to be acceptable,<xref rid="tca12405-bib-0007" ref-type="ref">7</xref> it is still possible that a tumor might be significantly enlarged between RTP and SBRT, as shown in this case. Optimal management in this scenario requires further investigation. A recent textbook considered the concept of re&#x2010;examination using CBCT and re&#x2010;simulation for adaptive SBRT to tailor technical aspects of treatment, as up to 32% of patients experienced significant changes in their tumor during SBRT.<xref rid="tca12405-bib-0009" ref-type="ref">9</xref>, <xref rid="tca12405-bib-0010" ref-type="ref">10</xref>, <xref rid="tca12405-bib-0011" ref-type="ref">11</xref> Significant dosimetric improvement could be achieved by tailoring SBRT to each patient after reassessing tumor growth before proceeding with SBRT.</p>
      <p>In conclusion, to our knowledge, we report the first case to show significant tumor progression specifically just before planned SBRT (not before RTP or during SBRT). Volumetric image guidance is crucial to identify this potential clinical scenario, although optimal management requires further investigation.</p>
    </sec>
    <sec id="tca12405-sec-0005">
      <title>Disclosure</title>
      <p>No authors report any conflict of interest.</p>
    </sec>
  </body>
  <back>
    <ack id="tca12405-sec-0004">
      <title>Acknowledgments</title>
      <p>This work was supported by the China Medical University Hospital (DMR&#x2010;105&#x2010;046, Taiwan). The corresponding author would like to thank Dr Chang J. Y. for mentoring in SBRT.</p>
    </ack>
    <ref-list id="tca12405-bibl-0001" content-type="cited-references">
      <title>References</title>
      <ref id="tca12405-bib-0001">
        <label>1</label>
        <mixed-citation publication-type="journal" id="tca12405-cit-0001">
<string-name>
<surname>Timmerman</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Paulus</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Galvin</surname>
<given-names>J</given-names>
</string-name>
<italic>et al.</italic>
<article-title>Stereotactic body radiation therapy for inoperable early stage lung cancer</article-title>. <source>JAMA</source>
<year>2010</year>; <volume>303</volume>: <fpage>1070</fpage>&#x2013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">20233825</pub-id></mixed-citation>
      </ref>
      <ref id="tca12405-bib-0002">
        <label>2</label>
        <mixed-citation publication-type="journal" id="tca12405-cit-0002">
<string-name>
<surname>Chang</surname>
<given-names>JY</given-names>
</string-name>, <string-name>
<surname>Senan</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Paul</surname>
<given-names>MA</given-names>
</string-name>
<italic>et al.</italic>
<article-title>Stereotactic ablative radiotherapy versus lobectomy for operable stage I non&#x2010;small&#x2010;cell lung cancer: A pooled analysis of two randomised trials</article-title>. <source>Lancet Oncol</source>
<year>2015</year>; <volume>16</volume>: <fpage>630</fpage>&#x2013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">25981812</pub-id></mixed-citation>
      </ref>
      <ref id="tca12405-bib-0003">
        <label>3</label>
        <mixed-citation publication-type="journal" id="tca12405-cit-0003">
<string-name>
<surname>Guo</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Zhuang</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Yuan</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>P</given-names>
</string-name>. <article-title>Influence of different image&#x2010;guided tracking methods upon the local efficacy of CyberKnife treatment in lung tumors</article-title>. <source>Thorac Cancer</source>
<year>2015</year>; <volume>6</volume>: <fpage>255</fpage>&#x2013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">26273370</pub-id></mixed-citation>
      </ref>
      <ref id="tca12405-bib-0004">
        <label>4</label>
        <mixed-citation publication-type="journal" id="tca12405-cit-0004">
<string-name>
<surname>Chang</surname>
<given-names>JY</given-names>
</string-name>, <string-name>
<surname>Dong</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>H</given-names>
</string-name>
<italic>et al.</italic>
<article-title>Image&#x2010;guided radiation therapy for non&#x2010;small cell lung cancer</article-title>. <source>J Thorac Oncol</source>
<year>2008</year>; <volume>3</volume>: <fpage>177</fpage>&#x2013;<lpage>86</lpage>.<pub-id pub-id-type="pmid">18303441</pub-id></mixed-citation>
      </ref>
      <ref id="tca12405-bib-0005">
        <label>5</label>
        <mixed-citation publication-type="journal" id="tca12405-cit-0005">
<string-name>
<surname>Atallah</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Cho</surname>
<given-names>BC</given-names>
</string-name>, <string-name>
<surname>Allibhai</surname>
<given-names>Z</given-names>
</string-name>
<italic>et al.</italic>
<article-title>Impact of pretreatment tumor growth rate on outcome of early&#x2010;stage lung cancer treated with stereotactic body radiation therapy</article-title>. <source>Int J Radiat Oncol Biol Phys</source>
<year>2014</year>; <volume>89</volume>: <fpage>532</fpage>&#x2013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">24929163</pub-id></mixed-citation>
      </ref>
      <ref id="tca12405-bib-0006">
        <label>6</label>
        <mixed-citation publication-type="journal" id="tca12405-cit-0006">
<string-name>
<surname>Gunter</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Ali</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Matthiesen</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Machiorlatti</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Thompson</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Algan</surname>
<given-names>O</given-names>
</string-name>. <article-title>Gross tumour volume variations in primary non&#x2010;small&#x2010;cell lung cancer during the course of treatment with stereotactic body radiation therapy</article-title>. <source>J Med Imaging Radiat Oncol</source>
<year>2014</year>; <volume>58</volume>: <fpage>384</fpage>&#x2013;<lpage>91</lpage>.<pub-id pub-id-type="pmid">24592817</pub-id></mixed-citation>
      </ref>
      <ref id="tca12405-bib-0007">
        <label>7</label>
        <mixed-citation publication-type="journal" id="tca12405-cit-0007">
<string-name>
<surname>Murai</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Shibamoto</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Baba</surname>
<given-names>F</given-names>
</string-name>
<italic>et al.</italic>
<article-title>Progression of non&#x2010;small&#x2010;cell lung cancer during the interval before stereotactic body radiotherapy</article-title>. <source>Int J Radiat Oncol Biol Phys</source>
<year>2012</year>; <volume>82</volume>: <fpage>463</fpage>&#x2013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">21095073</pub-id></mixed-citation>
      </ref>
      <ref id="tca12405-bib-0008">
        <label>8</label>
        <mixed-citation publication-type="journal" id="tca12405-cit-0008">
<string-name>
<surname>Salamekh</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Rong</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Ayan</surname>
<given-names>AS</given-names>
</string-name>
<italic>et al.</italic>
<article-title>Inter&#x2010;fraction tumor volume response during lung stereotactic body radiation therapy correlated to patient variables</article-title>. <source>PLoS One</source>
<year>2016</year>; <volume>11</volume> (<issue>4</issue>): <fpage>e0153245</fpage>.<pub-id pub-id-type="pmid">27049962</pub-id></mixed-citation>
      </ref>
      <ref id="tca12405-bib-0009">
        <label>9</label>
        <mixed-citation publication-type="book" id="tca12405-cit-0009">
<string-name>
<surname>Wagner</surname>
<given-names>H</given-names>
</string-name>. <chapter-title>Non&#x2010;small cell lung cancer</chapter-title> In: <person-group person-group-type="editor"><name><surname>Gunderson</surname><given-names>LL</given-names></name></person-group>, <person-group person-group-type="editor"><name><surname>Tepper</surname><given-names>JE</given-names></name></person-group> (eds). <source>Clinical Radiation Oncology</source>, <edition>3rd</edition> edn. <publisher-name>Elsevier</publisher-name>, <publisher-loc>Philadelphia, PA</publisher-loc>
<year>2012</year>; <fpage>805</fpage>&#x2013;<lpage>38</lpage>.</mixed-citation>
      </ref>
      <ref id="tca12405-bib-0010">
        <label>10</label>
        <mixed-citation publication-type="journal" id="tca12405-cit-0010">
<string-name>
<surname>Bhatt</surname>
<given-names>AD</given-names>
</string-name>, <string-name>
<surname>El&#x2010;Ghamry</surname>
<given-names>MN</given-names>
</string-name>, <string-name>
<surname>Dunlap</surname>
<given-names>NE</given-names>
</string-name>
<italic>et al.</italic>
<article-title>Tumor volume change with stereotactic body radiotherapy (SBRT) for early&#x2010;stage lung cancer: Evaluating the potential for adaptive SBRT</article-title>. <source>Am J Clin Oncol</source>
<year>2015</year>; <volume>38</volume>: <fpage>41</fpage>&#x2013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">24513663</pub-id></mixed-citation>
      </ref>
      <ref id="tca12405-bib-0011">
        <label>11</label>
        <mixed-citation publication-type="journal" id="tca12405-cit-0011">
<string-name>
<surname>Qin</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Yoo</surname>
<given-names>DS</given-names>
</string-name>, <string-name>
<surname>Kelsey</surname>
<given-names>CR</given-names>
</string-name>, <string-name>
<surname>Yin</surname>
<given-names>FF</given-names>
</string-name>, <string-name>
<surname>Cai</surname>
<given-names>J</given-names>
</string-name>. <article-title>Adaptive stereotactic body radiation therapy planning for lung cancer</article-title>. <source>Int J Radiat Oncol Biol Phys</source>
<year>2013</year>; <volume>87</volume>: <fpage>209</fpage>&#x2013;<lpage>15</lpage>.<pub-id pub-id-type="pmid">23790773</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
